Monoclonal antibody · developed by Compugen
COM902 is an agent given intravenously every 3 weeks as monotherapy in dose-escalation and cohort-expansion studies in subjects with advanced cancers, including multiple myeloma and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04354246 | Phase 1 | Advanced Cancer | Completed | CGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerColon CancerHNSCCLung CancerMicrosatellite Stable Colorectal CarcinomaMSS-CRCMultiple MyelomaOvarian CancerPlasma Cell Neoplasm
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.
See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEN catalysts and pipeline →